On Sept 10, 2018, we posted in The Week in Review #28 news we found very interesting about Compugen (CGEN). The news announced that Compugen has dosed its first patient in Phase 1 clinical trial with its first-in class immunotherapy antibody product COM701 targeting the firm's in house discovered immune checkpoint protein PVRIG.
In The Week in Review article we wrote in the beginning, investors who heard about Compugen’s unparalleled discovery capabilities expected it to rapidly create . . .